Editorial: Do Some Glucagon-Like-Peptide-1 Receptor Agonists (GLP-1 RA) Reduce Macrovascular Complications of Type 2 Diabetes Mellitus? (A Commentary on the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) Trial)

Publisher： Bentham Science Publishers

E-ISSN： 1875-6212|14|5|469-473

ISSN： 1570-1611

Source： Current Vascular Pharmacology, Vol.14, Iss.5, 2016-09, pp. : 469-473

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Glucagon-Like Peptide-1 Receptor Agonists for Type 2 Diabetes: A Clinical Update of Safety and Efficacy

By  

Current Diabetes Reviews, Vol. 12, Iss. 4, 2016-10 ,pp. : 403-413

Bentham Science Publishers

Access to resources Recommend Favorite

Impact of GLP-1 and GLP-1 Receptor Agonists on Cardiovascular Risk Factors in Type 2 Diabetes

By  

Current Diabetes Reviews, Vol. 6, Iss. 4, 2010-07 ,pp. : 191-200

Bentham Science Publishers

Access to resources Recommend Favorite

Editorial: Can Glucagon Like Peptide 1 (GLP1) Agonists or Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors Ameliorate Non-Alcoholic Steatohepatitis in People with or without Diabetes?

By  

Current Vascular Pharmacology, Vol. 14, Iss. 6, 2016-10 ,pp. : 494-497

Bentham Science Publishers

Access to resources Recommend Favorite

GLP-1 receptor agonists in the treatment of Type 2 diabetes

By Ahrén Bo  

Diabetes Management, Vol. 3, Iss. 5, 2013-09 ,pp. : 401-413

Future Medicine

Access to resources Recommend Favorite

Glucagon-Like Peptide-1-Based Therapies for the Treatment of Type 2 Diabetes Mellitus

By Gallwitz Baptist  

Treatments in Endocrinology, Vol. 4, Iss. 6, 2005-01 ,pp. : 361-370

Adis International

Access to resources Recommend Favorite